JOHNSON & JOHNSON is 206.4x more valuable than Arcus Biosciences, Inc. by market capitalization ($574.10 B vs $2.78 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RCUS | JNJ |
|---|---|---|
| Market cap | $2.78 B | $574.10 B |
| US-listed rank | #1869 | #20 |
| Revenue (latest FY) | $247.00M | $94.19B |
| Net income (latest FY) | -$353.00M | $26.80B |
| Net margin | -142.9% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 567 | 984 |
JOHNSON & JOHNSON is 206.4x more valuable than Arcus Biosciences, Inc. by market capitalization ($574.10 B vs $2.78 B).
In their latest fiscal years, Arcus Biosciences, Inc. reported $247.00M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Arcus Biosciences, Inc. and JOHNSON & JOHNSON, or browse the full rankings.